XOMA Signs Antibody Discovery Collaboration With Arana

XOMA and Arana Therapeutics have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display library, and a suite of integrated information and data management systems.

Reportedly, Arana has agreed to pay XOMA a fee of $6m and XOMA will be entitled to milestone payments and royalties on product sales. Under the terms of the collaboration, XOMA will be fully reimbursed for all services it may provide to Arana under the agreement.

The new, proprietary antibody library covered by the agreement with Arana, is one of a series of proprietary antibody libraries being developed by XOMA scientists to overcome existing limitations in library design by combining best-in-class techniques with XOMA’s own proprietary and patent-protected technologies.

The company said that access to multiple libraries may offer a number of benefits to XOMA and its partners because it enables the use of libraries best suited to the needs of a particular discovery project.

Steven Engle, chairman and CEO at XOMA, said: “We are pleased to partner with Arana, a company with a strong presence and capabilities in the antibody field.”